Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Nippon Shokubai invests in APIs
by Jean-François Tremblay
October 9, 2017
| A version of this story appeared in
Volume 95, Issue 40
Nippon Shokubai is entering the business of producing active pharmaceutical ingredients (APIs) for peptide and nucleic acid drugs. The company will build a plant in Suita, Japan, where it opened an API synthesis lab last year. The facility will be able to produce APIs in quantities ranging from milligrams to kilograms. Nippon Shokubai, best known as the world’s largest producer of superabsorbent polymers used in diapers and sanitary pads, has a strategy to expand in the medical field over the next three years.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter